Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157457092> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2157457092 abstract "“Reverse” or “exclusion” payments to settle pharmaceutical patent lawsuitsare facilitated because the Hatch-Waxman Act has been interpreted to give180 days of generic exclusivity to the first generic company to file forFDA approval, whether or not that company succeeds in invalidating thepatent or finding a way to avoid infringement. As a result, the patenteecan “buy off” the first generic entrant, paying them to delay their entryinto the market while still offering them the valuable period of genericexclusivity. And if that first generic is entitled to its 180 days, no oneelse can enter until after the exclusivity period has expired or beenforfeited. The result is that the 180-day exclusivity period is not servingits purpose of eliminating weak patents. True, it is encouraging lots ofchallenges to those patents. But it is encouraging the challengers toaccept compensation to drop those challenges, rather than taking them tojudgment and benefiting the rest of the world.We propose a change to the Hatch-Waxman statutory scheme. Our alternativeis straightforward: first-filing generic drug companies should be entitledto 180 days of exclusivity only if they successfully defeat the patentowner, for example, by invalidating the patent or by proving that they didnot infringe that patent. The point of 180-day exclusivity was to encouragechallenges to patents because the invalidation of bad patents benefitssociety as a whole. Society doesn’t benefit from a private deal to drop achallenge. That doesn’t mean settlement is never a good idea; it is acommonplace in our legal system. But it seems bizarre to insulate a companyfrom competition just because it settles the case. Indeed, we expect thatour proposal, if implemented, would facilitate more rational settlements,in which the settlements that result accurately reflect the likelihood ofsuccess in litigation." @default.
- W2157457092 created "2016-06-24" @default.
- W2157457092 creator A5088186426 @default.
- W2157457092 date "2016-08-24" @default.
- W2157457092 modified "2023-09-23" @default.
- W2157457092 title "Earning Exclusivity: Generic Drug Incentives and the Hatch-Waxman Act" @default.
- W2157457092 doi "https://doi.org/10.31235/osf.io/n32y8" @default.
- W2157457092 hasPublicationYear "2016" @default.
- W2157457092 type Work @default.
- W2157457092 sameAs 2157457092 @default.
- W2157457092 citedByCount "8" @default.
- W2157457092 countsByYear W21574570922012 @default.
- W2157457092 countsByYear W21574570922013 @default.
- W2157457092 countsByYear W21574570922014 @default.
- W2157457092 countsByYear W21574570922016 @default.
- W2157457092 countsByYear W21574570922017 @default.
- W2157457092 countsByYear W21574570922018 @default.
- W2157457092 crossrefType "posted-content" @default.
- W2157457092 hasAuthorship W2157457092A5088186426 @default.
- W2157457092 hasBestOaLocation W21574570922 @default.
- W2157457092 hasConcept C10138342 @default.
- W2157457092 hasConcept C118552586 @default.
- W2157457092 hasConcept C144133560 @default.
- W2157457092 hasConcept C145097563 @default.
- W2157457092 hasConcept C15744967 @default.
- W2157457092 hasConcept C158129432 @default.
- W2157457092 hasConcept C162324750 @default.
- W2157457092 hasConcept C17744445 @default.
- W2157457092 hasConcept C18903297 @default.
- W2157457092 hasConcept C190253527 @default.
- W2157457092 hasConcept C199539241 @default.
- W2157457092 hasConcept C2776396487 @default.
- W2157457092 hasConcept C2777063073 @default.
- W2157457092 hasConcept C2780035454 @default.
- W2157457092 hasConcept C2780757686 @default.
- W2157457092 hasConcept C2781127519 @default.
- W2157457092 hasConcept C29122968 @default.
- W2157457092 hasConcept C34447519 @default.
- W2157457092 hasConcept C86803240 @default.
- W2157457092 hasConcept C91306197 @default.
- W2157457092 hasConceptScore W2157457092C10138342 @default.
- W2157457092 hasConceptScore W2157457092C118552586 @default.
- W2157457092 hasConceptScore W2157457092C144133560 @default.
- W2157457092 hasConceptScore W2157457092C145097563 @default.
- W2157457092 hasConceptScore W2157457092C15744967 @default.
- W2157457092 hasConceptScore W2157457092C158129432 @default.
- W2157457092 hasConceptScore W2157457092C162324750 @default.
- W2157457092 hasConceptScore W2157457092C17744445 @default.
- W2157457092 hasConceptScore W2157457092C18903297 @default.
- W2157457092 hasConceptScore W2157457092C190253527 @default.
- W2157457092 hasConceptScore W2157457092C199539241 @default.
- W2157457092 hasConceptScore W2157457092C2776396487 @default.
- W2157457092 hasConceptScore W2157457092C2777063073 @default.
- W2157457092 hasConceptScore W2157457092C2780035454 @default.
- W2157457092 hasConceptScore W2157457092C2780757686 @default.
- W2157457092 hasConceptScore W2157457092C2781127519 @default.
- W2157457092 hasConceptScore W2157457092C29122968 @default.
- W2157457092 hasConceptScore W2157457092C34447519 @default.
- W2157457092 hasConceptScore W2157457092C86803240 @default.
- W2157457092 hasConceptScore W2157457092C91306197 @default.
- W2157457092 hasLocation W21574570921 @default.
- W2157457092 hasLocation W21574570922 @default.
- W2157457092 hasOpenAccess W2157457092 @default.
- W2157457092 hasPrimaryLocation W21574570921 @default.
- W2157457092 hasRelatedWork W1571378691 @default.
- W2157457092 hasRelatedWork W1895768774 @default.
- W2157457092 hasRelatedWork W2107929561 @default.
- W2157457092 hasRelatedWork W2108936692 @default.
- W2157457092 hasRelatedWork W2355647380 @default.
- W2157457092 hasRelatedWork W2391015470 @default.
- W2157457092 hasRelatedWork W2788325686 @default.
- W2157457092 hasRelatedWork W3084660554 @default.
- W2157457092 hasRelatedWork W3126083577 @default.
- W2157457092 hasRelatedWork W3146304957 @default.
- W2157457092 isParatext "false" @default.
- W2157457092 isRetracted "false" @default.
- W2157457092 magId "2157457092" @default.
- W2157457092 workType "article" @default.